VJHemOnc Podcast cover image

iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more

VJHemOnc Podcast

00:00

Mutations in ELN 2022, CPX351, and Challenges in HM-A-Venn

Discussion on MDS-related mutations in ELN 2022, including RUNKS-1 and its poor prognosis association. Highlighting the survival benefit of CPX351 compared to other chemotherapy regimens and the need for further investigation.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app